Biogen Idec Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it anticipates the trial on the Massachusetts Department of Revenue’s US$38.9 million tax assessment against its wholly owned subsidiary,…
Biogen Idec Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the European Commission, or the EC, published its final report on an inquiry in July 2009 in which it…
Biogen Idec Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that on June 15, 2009, a panel issued its final decision in the arbitration filed by the Company against Genentech,Inc.…
Mediation on outstanding claims filed against Biogen Idec Inc. and its subsidiary Biogen Inc. (n/k/a Biogen Idec MA Inc.) over certain drugs for which Medicaid provides reimbursement (covered drugs) is still ongoing, The Company disclosed in its latest quarterly report…
Biogen Idec Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is cooperating with the U.S. Department of Justice in its investigation of Genentech related to the promotion of…
Biogen Idec Inc. continues to defend itself in a lawsuit captioned United States of America ex rel. Paul P. McDermott v. Genentech Inc. and Biogen Idec Inc., filed on Jan. 6, 2006, in the U.S. District Court of the District…
An informal mediation on a lawsuit filed by the Attorney General of Arizona against Biogen Idec Inc. along with several other major pharmaceutical and biotechnology companies, in the Superior Court of the State of Arizona, is ongoing.
The complaint, transferred…
Mediation on outstanding claims filed against Biogen Idec Inc. and its subsidiary Biogen Inc. (n/k/a Biogen Idec MA Inc.) over certain drugs for which Medicaid provides reimbursement (covered drugs) is still ongoing.
Along with several other major pharmaceutical and biotechnology…
The U.S. Department of Justice’s investigation of Genentech, Inc. relating to the promotion of RITUXAN, a cancer medication used in combination with other cancer medicines to treat non-Hodgkin’s lymphoma, is ongoing.
Biogen Idec Inc. markets RITUXAN in the U.S. in…
Biogen Idec Inc. continues to cooperate with the European Commission’s industry-wide antitrust inquiry into competitive conditions within the pharmaceutical sector.
As part of the inquiry that began on January 2008, the EC issued detailed questionnaires to about 100 companies, including the…